No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

No­var­tis will pay $150 mil­lion up­front to Schrödinger, in a pact an­nounced Tues­day to work to­geth­er on sev­er­al pre­clin­i­cal drug pro­grams.

Found­ed in 1990, Schr …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER